Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Adverse effects (non‐serious) · participants with hidradenitis suppurativa
Topical clindamycin showed no clear difference in adverse effects (non‐serious) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects (4 to 8 weeks) · eczema
1 finding from 1 review
Adverse events associated with treatment · children and adolescents with active morphea (linear scleroderma, generalised morphea and mixed subtype: linear and circumscribed).
Oral methotrexate and oral prednisone showed no clear difference in primary outcome: Adverse effects compared with placebo and oral prednisone (low certainty).
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of serious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous leishmaniasis
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (long‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Thymopentin showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
HSV vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Yellow fever vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found